0.69 -0.032 (-4.49%) | 04-26 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 1.37 | 1-year : | 1.75 |
Resists | First : | 1.17 | Second : | 1.5 |
Pivot price | 0.94 | |||
Supports | First : | 0.64 | Second : | 0.54 |
MAs | MA(5) : | 0.73 | MA(20) : | 1.01 |
MA(100) : | 1.71 | MA(250) : | 1.29 | |
MACD | MACD : | -0.2 | Signal : | -0.2 |
%K %D | K(14,3) : | 4.2 | D(3) : | 3 |
RSI | RSI(14): 28 | |||
52-week | High : | 3.55 | Low : | 0.17 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CDIO ] has closed above bottom band by 11.0%. Bollinger Bands are 28.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 0.74 - 0.75 | 0.75 - 0.75 |
Low: | 0.64 - 0.64 | 0.64 - 0.65 |
Close: | 0.68 - 0.69 | 0.69 - 0.7 |
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
Wed, 24 Apr 2024
As the Use of AI In Healthcare Grows, Cardio Diagnostic Is Using It In Quest to Help Prevent Cardiovascular Disease - Nasdaq
Tue, 23 Apr 2024
As the Use of AI In Healthcare Grows, Cardio Diagnostic Is Using It In Quest to Help Prevent Cardiovascul - Benzinga
Thu, 11 Apr 2024
Cardio Diagnostics Inks Groundbreaking Telehealth Agreement With Navierre And Expands Access To Cardiovas - Benzinga
Thu, 04 Apr 2024
Cardio Diagnostics Holdings, Inc. Enters Into a Nationwide Telehealth Agreement with Navierre - Business Wire
Wed, 03 Apr 2024
Cardio Diagnostics Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Tue, 02 Apr 2024
Cardio Diagnostics Unveils New Investor Engagement Materials - TipRanks.com - TipRanks
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 22 (M) |
Held by Insiders | 1.767e+007 (%) |
Held by Institutions | 17.7 (%) |
Shares Short | 494 (K) |
Shares Short P.Month | 0 (K) |
EPS | -7.13e+006 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -29 % |
Return on Assets (ttm) | 39.5 % |
Return on Equity (ttm) | -84.6 % |
Qtrly Rev. Growth | 17070 % |
Gross Profit (p.s.) | 92.33 |
Sales Per Share | -46.44 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -0.7 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -6 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.02 |
Price to Cash Flow | 24.49 |
Dividend | 0 |
Forward Dividend | 444630 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |